dc.contributorUniversidade Estadual de Maringá (UEM)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Estadual de Londrina (UEL)
dc.date.accessioned2014-05-20T15:33:40Z
dc.date.accessioned2022-10-05T17:16:45Z
dc.date.available2014-05-20T15:33:40Z
dc.date.available2022-10-05T17:16:45Z
dc.date.created2014-05-20T15:33:40Z
dc.date.issued2012-08-01
dc.identifierInternational Journal of Immunogenetics. Hoboken: Wiley-blackwell, v. 39, n. 4, p. 296-302, 2012.
dc.identifier1744-3121
dc.identifierhttp://hdl.handle.net/11449/42232
dc.identifier10.1111/j.1744-313X.2012.01088.x
dc.identifierWOS:000306078300004
dc.identifier6322604200510676
dc.identifier7788448564326585
dc.identifier0000-0002-4035-9486
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3913097
dc.description.abstractThe objective of this study was to analyse the possible role of HLA polymorphism of chronically infected hepatitis C virus patients in the response outcome to treatment with pegylated interferon-alpha plus ribavirin. To that end, 144 Brazilian patients infected only with genotype 1 of the virus were treated with pegylated interferon-alpha at 1.5 mu g kg-1 in conjunction with ribavirin (1000 mg if patient weight was <75 kg and 1250 mg if >75 kg) for 48 weeks. The patients did not have concomitant HBV or HIV infections or liver disease, did not undergo previous antiviral treatment, and were followed up for 24 weeks after the end of treatment to assure they presented a sustained virological response. Patients were classified according to response to treatment in responsive (SVR), nonresponsive (NRS) and relapsers (REL). HLA class I and class II typing were carried out through PCR-SSO using Luminex technology. A statistically higher frequency of DRB1*11 patients was observed in the SVR group (39.6% vs. 14.3%P = 0.0012; Pc = 0.0156; OR = 3.94; 95% CI = 1.88.8). HLA-DQB1*03 patients were also more frequent in the SVR group, but the P value lost significance after Bonferroni correction (62.3% vs. 41.7%P = 0.024; Pc = 0.14, OR = 2.3; 95% CI = 1.144.60). HLA class II antigens can positively influence the response to treatment with pegylated interferon-alpha and ribavirin.
dc.languageeng
dc.publisherWiley-Blackwell
dc.relationInternational Journal of Immunogenetics
dc.relation1.000
dc.relation0,403
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.titleInfluence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C
dc.typeArtigo


Este ítem pertenece a la siguiente institución